Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference.

Presentation Details:

34th Annual Roth Conference

https://www.roth.com/conferences/upcoming-conferences Date: March 14, 2022Time: 1:30pm Pacific TimeLocation: The Ritz Carlton, Laguna Niguel located in Dana Point, California

Maxim’s 2022 Virtual Growth Conference

https://www.m-vest.com/home Date: March 30, 2022Time: 4:30pm Eastern TimeLocation: https://m-vest.com/events/2022-virtual-growth-conference

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced  severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:   

Monopar Therapeutics Inc. Investor Relations   Kim R. Tsuchimoto   Chief Financial Officer   kimtsu@monopartx.com 

Follow Monopar on social media for updates:  Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics